Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome-Reference-Cited by-同舟云学术

Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcome

Published:2020-02-22 Issue:4 Volume:99 Page:773-780
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Bouchacourt B.^ORCID,Hospital M. A.,Zemmour C.,Rey J.,d’Incan E.,Charbonnier A.,Mohty B.,Saillard C.,Bonnet S.,Collignon A.,Gelsi-Boyer V.,Mozziconacci M. J.,Blaise D.,Vey N.

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-020-03922-w.pdf

Reference27 articles.

1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

2. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79(8):1924–1930

3. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331(14):896–903

4. Estey E, Döhner H (2006) Acute myeloid leukaemia. Lancet Lond Engl 368(9550):1894–1907

5. Estey EH (2000) How I treat older patients with AML. Blood 96(5):1670–1673

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT ^TMBlood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience;BLOOD TRANSFUS-ITALY;2023

2. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway;International Immunopharmacology;2022-03

3. A case of therapy-related acute lymphoblastic leukemia following the treatment of acute myeloid leukemia;Leukemia Research Reports;2022

4. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes;Blood Cancer Journal;2021-11

5. Optimizing Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia;Stem Cells Translational Medicine;2021-11-01